Immunome, Inc. IMNM

Immunome has delivered a powerful multi year share price run, and the question now is whether the current US$21.51 price lines up with the cash flows that can support it. With the spotlight on its pipeline progress, the valuation story increasingly comes back to what the company’s future cash generation may justify. Immunome’s share price has gained 186.4% over the past 3 years, which puts a lot of weight on whether its cash flows can eventually back up that kind of move. The recent FDA...

BOTHELL, Wash., September 30, 2026--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IM-1340, a potential first-in-class antibody-drug conjugate (ADC) for the treatment of advanced solid tumors.